(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Explainer-What will change with the US reclassification of marijuana? - 2See tonight’s solar storm unfold across the world
- 3'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 4Instructions to Explore the Universe of Vehicle Leases
- 5Churches and politicians in South Sudan call for 'lasting peace' in Easter messages
- Happy with Running Shoes for 2024
- Instructions to Investigate Different Open Record Extra Offers Actually
- What is the Insurrection Act? Can Trump really use the military to 'put an end' to Minneapolis ICE protests?
- 10 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- Russia Establishing Long-Range Drone Bases In Belarus, Warns Ukraine
- Inflammatory Merz remarks on migrants' violence against women slammed
- 'Crammed into a cell with vermin at New Year'
- Watch This Glacier Race into the Sea
- AfD faction in western Germany ousts councilman for firebrand speech
